A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer

PURPOSE: The prognosis for locally advanced breast cancer (LABC) patients continues to be poor, with an estimated five-year survival of only 50–60%. Preclinical data demonstrates enhanced therapeutic efficacy with liposomal encapsulation of doxorubicin combined with hyperthermia (HT). Therefore this...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vujaskovic, Zeljko, Kim, Dong W., Jones, Ellen, Lan, Lan, McCall, Linda, Dewhirst, Mark W., Craciunescu, Oana, Stauffer, Paul, Liotcheva, Vlayka, Betof, Allison, Blackwell, Kimberly
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2956498/
https://ncbi.nlm.nih.gov/pubmed/20377362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/02656731003639364
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires